Pathology and Laboratory Medicine at NewYork-Presbyterian Queens
56-45 Main Street
Flushing, NY 11355
New and Existing Patients
Already a patient?
Login or sign-upto Connect Patient Portal to make an appointment
Locations and Appointments
About William Harry Rodgers, Ph.D., M.D.
Dr. Rodgers has distinguished himsef as a clinical pathologist, educator and academic medical administrator. He has jonted NYHQ as Chair of Pathology and will continue to support the growing oncology and surgical programs on NYHQ to expand and strengthen outpatient laboratory operations and to support the graduate medical educational activities.
Board Certifications
- Anatomic Pathology and Clinical Pathology
- Cytopathology
Expertise
- Gynecologic Pathology
- Laboratory Medicine
- Perinatal Pathology
Education
- Degrees: Indiana University
- Degrees: University of Rochester
- Degrees: University of Rochester School of Medicine and Dentistry
Languages
- English
Titles & Positions
- Attending Pathologist
- Professor of Clinical Pathology and Laboratory Medicine
Hospital Affiliations
- NewYork-Presbyterian Brooklyn Methodist Hospital
- NewYork-Presbyterian Queens Hospital
Education
- Degrees: University of Rochester School of Medicine and Dentistry
- Degrees: University of Rochester
- Degrees: Indiana University
Titles & Positions
- Attending Pathologist
- Professor of Clinical Pathology and Laboratory Medicine
Board Certifications
- anatomic pathology and clinical pathology
- cytopathology
Languages Spoken
- english
Research
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.
February 17, 2026Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).
December 12, 2025Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263).
October 06, 2025